Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (161-170 of 457) with videos related to

Pageof 46
Sort By:
American Journal of Hematology|September 4, 2025
Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With High-Risk Myeloid Neoplasms Based on GvHD Prophylaxis: PTCy Vs. TAC/MTXKhalil Hassan, Anmol Baranwal, Al Rabee Kassis, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 20, 2016
Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemiaMehrdad Hefazi, Moussab Damlaj, Hassan B Alkhateeb, et al.
Leukemia Research|July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patientsJustin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Leukemia Research|July 18, 2018
Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblastsAbhishek A Mangaonkar, Naseema Gangat, Aref Al-Kali, et al.
Bone Marrow Transplantation|April 5, 2025
Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysisAnmol Baranwal, Rabee Kassis, Khalil Hassan, et al.
Haematologica|July 2, 2026
Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic seriesAshya R Burgess, Husnain Ali, Jabra Zarka, et al.
Mayo Clinic Proceedings|August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013Aref Al-Kali, Darci Zblewski, James M Foran, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 14, 2015
Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based SurveyEun-Ju Lee, B Douglas Smith, Jessica W Merrey, et al.
British Journal of Haematology|May 26, 2022
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experienceNaseema Gangat, Kristen McCullough, Aref Al-Kali, et al.
Blood Advances|March 31, 2022
Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agentsIsla M Johnson, Evandro D Bezerra, Faiqa Farrukh, et al.
Pageof 46

Showing results (161-170 of 457) with videos related to

Sort By:
Pageof 46
American Journal of Hematology|September 4, 2025
Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With High-Risk Myeloid Neoplasms Based on GvHD Prophylaxis: PTCy Vs. TAC/MTXKhalil Hassan, Anmol Baranwal, Al Rabee Kassis, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 20, 2016
Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemiaMehrdad Hefazi, Moussab Damlaj, Hassan B Alkhateeb, et al.
Leukemia Research|July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patientsJustin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Leukemia Research|July 18, 2018
Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblastsAbhishek A Mangaonkar, Naseema Gangat, Aref Al-Kali, et al.
Bone Marrow Transplantation|April 5, 2025
Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysisAnmol Baranwal, Rabee Kassis, Khalil Hassan, et al.
Haematologica|July 2, 2026
Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic seriesAshya R Burgess, Husnain Ali, Jabra Zarka, et al.
Mayo Clinic Proceedings|August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013Aref Al-Kali, Darci Zblewski, James M Foran, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 14, 2015
Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based SurveyEun-Ju Lee, B Douglas Smith, Jessica W Merrey, et al.
British Journal of Haematology|May 26, 2022
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experienceNaseema Gangat, Kristen McCullough, Aref Al-Kali, et al.
Blood Advances|March 31, 2022
Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agentsIsla M Johnson, Evandro D Bezerra, Faiqa Farrukh, et al.
Pageof 46